Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cuenot
- Ownership
- Private
- Development stage
- Other
01
Overview
Cuenot is a biotechnology company focused on developing next-generation small molecule inhibitors targeting the NLRP3 inflammasome and Caspase-1 pathways. The company's research aims to address a wide range of chronic inflammatory and autoimmune conditions by modulating the body's innate immune response. By focusing on highly specific inhibition of these key inflammatory drivers, Cuenot seeks to provide more effective and safer therapeutic options for patients with high unmet medical needs. The company is currently in the pre-clinical stage, advancing its lead candidates through optimization and early validation studies.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Cuenot.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cuenot.